{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:51:24Z","timestamp":1789595484955,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.003","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T16:47:34Z","timestamp":1729097254000},"page":"1010-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1932-3012","authenticated-orcid":false,"given":"Yaohan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzi","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.003_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0002","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/hae.14603","article-title":"The long-term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: population-based predictions from 2018 to 2033","volume":"28","author":"He","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0004","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"5 Suppl","key":"10.1016\/j.clinthera.2024.09.003_bib0005","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/13696998.2017.1405816","article-title":"Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden","volume":"21","author":"Henry","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0007","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/17474086.2017.1386096","article-title":"The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China","volume":"10","author":"Wu","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0031-1300954","article-title":"Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0009","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/hae.13198","article-title":"A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment","volume":"23","author":"Wu","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CEOR.S16670","article-title":"Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A","volume":"3","author":"Colombo","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0011","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/hae.13185","article-title":"Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy","volume":"23","author":"Coppola","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0012","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S0266462316000544","article-title":"Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia Type A in Colombia","volume":"32","author":"Castro Jaramillo","year":"2016","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0013","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/16078454.2021.1885123","article-title":"A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran","volume":"26","author":"Zahedi","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0014","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1017\/S0266462309990420","article-title":"Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran","volume":"25","author":"Daliri","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0015","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/hae.14863","article-title":"Treatment-related outcome from patient report outcome (PRO) of children with severe and moderate hemophilia A in China: an analysis report of registration data from patient organization \"Hemophilia Home Care Center\"","volume":"29","author":"Guan","year":"2023","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2024.09.003_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0017","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0019","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0020","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.clinthera.2021.07.004","article-title":"Cost-effectiveness analysis of prophylaxis versus on-demand treatment for children with hemophilia B without inhibitors in China","volume":"43","author":"Liu","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0021","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0022","unstructured":"National Bureau of Statistics. http:\/\/www.stats.gov.cn."},{"key":"10.1016\/j.clinthera.2024.09.003_bib0023","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2516.2008.01664.x","article-title":"Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A","volume":"14","author":"Risebrough","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0024","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.120370","article-title":"RANK-RANKL-OPG in hemophilic arthropathy: from clinical and imaging diagnosis to histopathology","volume":"39","author":"Melchiorre","year":"2012","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.003_bib0025","article-title":"The impact of haemophilia complications on health-related quality of life for adults with severe haemophilia","volume":"16","author":"Mazza","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0026","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/13696998.2021.1965388","article-title":"Cost of hemophilia A in Turkey: an economic disease burden analysis","volume":"24","author":"Malhan","year":"2021","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2024.09.003_bib0027","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia A","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:00:19Z","timestamp":1733860819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002662"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}